Welcome to our dedicated page for NASDAQ news (Ticker: nasdaq), a resource for investors and traders seeking the latest updates and insights on NASDAQ stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NASDAQ's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NASDAQ's position in the market.
The Joint Corp (NASDAQ: JYNT) was named to the Franchise Times Top 400 for 2025, ranking 139 and moving up 11 spots year-over-year. This marks the company's sixth year inside the top 200 franchised systems by global, systemwide sales. The company highlighted growth across the health and medical and personal services sectors and emphasized its retail clinic model offering no-appointment, no-insurance-hassle, affordable chiropractic care with extended hours. Leadership said the ranking validates the brand and supports continued expansion to increase access to routine chiropractic services nationwide.
Atossa Therapeutics (NASDAQ: ATOS) amended its Phase 2 EVANGELINE study of (Z)-endoxifen in premenopausal ER+/HER2– early breast cancer to a single-arm, open-label, non-registrational design. The amendment reduces planned enrollment from 214 to 40–65 patients, implements a Cohort A two-stage futility rule using Week-4 Ki-67 ≤10% for earlier go/no-go decisions, and retains unchanged patient-safety data collection and DSMC oversight. Run-in data showed a Week-4 Ki-67 ≤10% rate of 86%. The company says the change aims to cut future study costs, accelerate objective readouts, and prioritize NDA-enabling activities in 2026.
Core Natural Resources (NYSE: CNR) reported Q2 2025 financial results, highlighting $220.2 million in operating cash flow and $131.1 million in free cash flow. The company posted a net loss of $36.6 million ($0.70 per share) and adjusted EBITDA of $144.3 million. Core increased its merger-related annual synergies target to $150-170 million.
Key operational highlights include $1.1 billion in revenues, return of $87.1 million to stockholders through buybacks and dividends, and strong performance in high c.v. thermal coal and Powder River Basin segments. The company maintains $948 million in total liquidity, including $413 million in cash. Core expects to resume longwall production at Leer South by end of October 2025, with anticipated insurance recoveries exceeding $100 million.
Fusion Connect has secured an $85 million term loan from Hark Capital through a NAV-based loan agreement. The funding will be allocated for operating capital, debt reduction, and strategic investments to accelerate growth. The company, specializing in cloud communications services, plans to invest in talent, technology, infrastructure, customer service, and product development.
Fusion Connect differentiates itself by offering a comprehensive suite of communications services with an all-US-based support team, backed by a 100% uptime guarantee. The company focuses on serving mid-market and enterprise organizations, particularly those with multi-location operations.
Summary not available.
Summary not available.
Akorn Operating Company LLC has filed for Chapter 7 bankruptcy as of February 23, 2023, ceasing all operations and terminating its US staff. As a result, the company is initiating a voluntary recall of various human and animal drug products that are within their expiry dates. The recall is due to the discontinuation of quality activities, which prevents assurance that products meet intended specifications and may render them adulterated. There are no reports of adverse events related to the recall. Akorn is notifying distributors, requesting that affected products be discarded, and advising consumers to contact their healthcare providers if they have concerns about products in their possession. For further inquiries, consumers can reach Akorn at the specified hotline during business hours.
Akorn Operating Company has launched the first-to-market generic Cetrorelix Acetate for Injection at the ASRM Conference in Anaheim, California. This product serves as a lower-cost alternative for patients undergoing Assisted Reproductive Technology (ART). The FDA granted Akorn a Competitive Generic Therapy designation for Cetrorelix, entitling it to 180 days of market exclusivity. U.S. sales of Cetrorelix are projected at approximately $127 million for 2022, with the drug aimed at preventing premature ovulation during fertility treatments.
Byrna Technologies Inc. (NASDAQ: BYRN) has sold its 40mm legacy business's IP and tooling to Facta Global, retaining exclusive rights to sell the product in the U.S. and South Africa. The deal includes cash and future royalties. Following production issues at its contract manufacturer, Byrna aims to resume supplying the 40mm BIP to U.S. law enforcement as early as July. The partnership with Facta Global, which has extensive experience in law enforcement training and is Byrna's long-time distributor, positions both companies for growth in the less-lethal product market.
Byrna Technologies (NASDAQ: BYRN) reported Q2FY22 revenues of $11.6 million, down 13.3% from $13.4 million in Q2FY21. The company experienced a net loss of $(3.0) million compared to a net income of $2.0 million in the same quarter last year. Gross margin decreased to 52.7% from 56.4%, attributed to higher freight costs and a rise in lower-margin international sales. Byrna reiterated its full-year revenue guidance of $55 - $60 million, aiming for growth through new product launches and market expansion, including the recent acquisition of Fox Labs International.